National Institutes of Health

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

Invizyne is a biotechnology company focused on revolutionizing biomanufacturing through the development of innovative enzyme-based systems. The company specializes in designing enzymes and constructing cell-free enzymatic pathways that operate continuously and independently outside of living cells. This approach addresses many challenges associated with traditional cell-based biomanufacturing technologies. Invizyne's flagship platform, SimplePath, aims to efficiently convert natural and renewable resources into a variety of valuable chemicals, including pharmaceuticals, fuels, materials, and food additives. By providing a modular and cascading system, Invizyne seeks to offer a viable alternative to conventional methods of chemical production, such as chemical synthesis and natural extraction, thereby enhancing the efficiency and sustainability of the biomanufacturing process.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for pain management. The company addresses significant unmet needs in both chronic and acute pain treatment, moving beyond traditional systemic approaches. Its flagship product, Neural Ice™, is a drug-free injectable therapy designed to provide safe and effective pain relief through reversible inhibition of nerve activity. This novel solution offers patients a long-lasting relief period, with effectiveness extending from thirty to sixty days following a single injection. By prioritizing non-addictive and locally targeted therapies, Brixton Biosciences aims to transform pain management practices and improve the quality of life for patients suffering from various forms of pain.

ATCC global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While maintaining traditional collection materials, ATCC develops high-quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

Rosalind Franklin University of Medicine and Science, established in 1912, is a North Chicago, Illinois-based institution dedicated to educating future health science leaders. It comprises five schools offering degrees such as Doctor of Medicine, Doctor of Podiatric Medicine, Nurse Anesthesia, Physical Therapy, and Physician's Assistant. The university fosters research and provides opportunities for students to engage in it, both on campus and through partnerships with nearby institutions. It aims to enrich students' lives professionally, mentally, and socially through various organizations and activities. Admission requirements vary by school but generally seek students with a strong scientific background and leadership skills. The university offers financial aid to eligible students who demonstrate need.

Resvita Bio is a biotechnology company focused on developing and manufacturing engineered probiotics specifically designed to treat various skin-related diseases, including cancer. The company utilizes synthetic biology and metabolic engineering to create a versatile skin microbial platform. This platform aims to deliver therapies that reduce inflammation, repair damaged tissue, and eliminate harmful bacteria, offering faster and more effective treatment options for chronic skin conditions.

Tiziana Life Sciences is a clinical-stage biotechnology company based in London, UK, focused on discovering and developing novel therapeutic molecules for oncology and immunology. The company's product pipeline includes Foralumab, a human anti-CD3 monoclonal antibody aimed at treating autoimmune and inflammatory diseases such as graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently undergoing phase II clinical trials for epithelial thymic carcinoma. Additionally, Tiziana is developing Anti IL-6r, a monoclonal antibody targeting interleukin-6 for severe COVID-19 cases, and StemPrintER, a multi-gene signature assay for estrogen-receptor positive breast cancer patients. Founded in 2013, Tiziana Life Sciences is dedicated to advancing innovative therapies for serious diseases, including neurodegenerative disorders and lung diseases.

Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.

Immunovia is a diagnostics company focused on the early detection of pancreatic cancer and other complex diseases. It develops and commercializes innovative diagnostic tools using its proprietary technology platform, IMMray, which is based on antibody microarray analysis. The company conducts clinical trials and validation studies to ensure the accuracy and reliability of its tests. By collaborating with medical institutions and research centers worldwide, Immunovia aims to bring its diagnostic solutions to market, significantly impacting the treatment and management of pancreatic cancer and potentially improving survival rates. Its approach to utilizing blood-based biomarkers may also enable early detection strategies for other cancers and autoimmune diseases.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Matter Bio is a biotechnology company dedicated to preserving genomic integrity. It offers research services aimed at enhancing longevity by safeguarding and utilising DNA information. The company's primary focus is assembling an elite team of scientists and executives to combat genetic mutations and extend patient lifespan through innovative approaches to reverse such mutations.

Selsym Biotech is a biotechnology company focused on developing innovative therapies for uncontrolled bleeding. Their primary product, Hemostatic Healing Hydrogels (H3), is designed to control bleeding in trauma and surgery situations. This therapy addresses critical issues such as platelet supply shortages and shelf life limitations, aiming to revolutionize hemorrhage control in emergency and surgical settings.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Lamassu Pharma is a biotech startup dedicated to addressing the critical unmet medical need for severe acute pancreatitis. The company is focused on developing a novel small molecule therapy that has shown significant preclinical efficacy in mitigating mortality and morbidity associated with this condition. This therapeutic candidate was developed by leading scientists at Mayo Clinic and aims to improve medical outcomes for patients suffering from severe acute pancreatitis. Currently, Lamassu Pharma is engaged in safety testing of this compound in preparation for definitive clinical trials, with the ultimate goal of saving lives and enhancing the treatment landscape for this serious disease.

Maxim Biotech provides vitro diagnostic testing development and testing solutions.

AcuraStem is a biotechnology company based in Monrovia, California, founded in 2016. The company specializes in developing a precision medicine platform that utilizes complex cellular models derived from Amyotrophic Lateral Sclerosis (ALS) patients' cells. AcuraStem employs advanced cellular reprogramming and artificial intelligence technologies to create patient-specific treatments for neurodegenerative diseases. Their platform is designed to evaluate disease progression and test existing therapeutics, as well as combinations of therapeutic approaches, to identify effective treatments that could slow disease progression. The company's team includes PhDs, professors, tech entrepreneurs, and veterans from the drug industry, all working towards addressing the challenges posed by ALS.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

RNAConnect specializes in developing enzymatic tools for visualizing and manipulating RNA, with a focus on low-abundance and long, structured RNAs. Their core product is a reverse transcriptase designed to provide greater visibility into these challenging RNA types and their various isoforms. This enzyme is optimized to synthesize cDNA with high fidelity and processivity, enabling researchers to study complex RNA template structures without the need for heat.

Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

The Stark Neurosciences Research Institute is dedicated to improving outcomes for persons suffering from disorders of the nervous system.

L2P Research Labs is a preclinical contract research organization (CRO) that specializes in providing comprehensive research and development support. The company offers a range of preclinical and toxicology services, utilizing advanced technologies such as quantitative whole-body animal imaging, small animal ultrasound, MRI, and CT scans. L2P Research Labs also provides proprietary orthotopic and metastatic tumor models, enabling researchers to access a complete suite of research services tailored to their needs. Through its innovative approaches and state-of-the-art facilities, the company supports the advancement of scientific research in the fields of medicine and drug development.

Rational Vaccines is a preclinical stage company focused on developing innovative vaccines to address herpes simplex virus-related diseases. The company is dedicated to creating live-attenuated viral immunotherapeutics and prophylactic vaccine candidates aimed at reducing the spread of the virus and improving the management of symptoms associated with herpes infections. Through its research, Rational Vaccines aspires to revolutionize the treatment, prevention, and diagnosis of herpes and related conditions, ultimately enhancing the quality of life for individuals affected by these diseases.

Integral Molecular, Inc. is a biotechnology company headquartered in Philadelphia, Pennsylvania, specializing in the development of innovative technologies for drug discovery targeting challenging diseases such as cancer, HIV, and arthritis. The company is particularly known for its Lipoparticle technology, which enhances the identification and optimization of drugs aimed at integral membrane proteins. With over 20 years of expertise in membrane proteins and antibodies, Integral Molecular has supported more than 400 pharmaceutical and biotechnology companies in their research, medication discovery, and vaccine development efforts. The company's solutions are integral to various stages of the drug discovery process, focusing on the development of chemical compounds and antibodies.

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

Omniose is an early-stage biotechnology company focused on the development of next-generation conjugate vaccines aimed at combating infectious diseases. The company specializes in pneumococcal conjugate vaccines that leverage proprietary in vivo conjugating technology, allowing for broader protection against various bacterial strains. By utilizing bioconjugation technology, Omniose's approach circumvents reliance on synthetic chemistry techniques, thereby enhancing the efficiency of vaccine development. This innovative platform supports the creation of polysaccharide-protein conjugate-based vaccines targeting multiple respiratory pathogens, including Streptococcus pneumoniae, ultimately enabling healthcare professionals to provide more effective treatment options for patients.

Base Pair Biotechnologies, Inc. is a biotechnology company based in Pearland, Texas, specializing in the research, development, and discovery of aptamer affinity ligands. Established in 2012, the company offers custom aptamer development services and a catalog of ready-made aptamers. Its innovative platform incorporates novel libraries and proprietary methods for multiplexing the aptamer discovery process, allowing for efficient screening and validation. Base Pair Biotechnologies collaborates with academic, commercial, and government institutions to create advanced tools and technologies across various sectors, including diagnostics, therapeutics, animal testing, agriculture, and environmental testing. The company's expertise in aptamer research, which began in 2004, has positioned it as a leader in the field, enabling clients to obtain high-quality aptamers with reduced time and cost.

Golden Helix is a developer of bioinformatics solutions specializing in genomic data analysis, with a focus on supporting life science research and translational medicine. With over 20 years of experience, the company provides innovative cloud-based software that empowers scientists and healthcare professionals to manage, analyze, and visualize complex genomic and phenotypic data. By streamlining the annotation and filtering of variants from next-generation sequencing, Golden Helix enables biologists and researchers of varying expertise to conduct intricate analyses and produce meaningful insights from large genomic datasets without the constant need for specialized bioinformatics support.

South Rampart Pharma is a clinical-stage biotechnology company dedicated to developing safer alternatives for pain management. It focuses on creating novel, non-opioid and non-hepatotoxic molecules that target the midbrain's periaqueductal grey region to alleviate acute pain. The company's lead candidate, SRP-001, has received FDA Fast Track designation and aims to reduce risks associated with current pain medications, such as abuse potential and liver toxicity.

Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Greenstone Biosciences is a drug discovery platform focused on accelerating the development of effective therapies for patients. By leveraging advanced technologies, including artificial intelligence and human-induced pluripotent stem cells, the company aims to transform the traditional drug discovery process, which is often slow and prone to high failure rates. Greenstone Biosciences seeks to create a rapid and integrated computational platform that can efficiently deliver safe and effective therapeutics, addressing diseases with significant unmet medical needs. Through its innovative approach, the company is dedicated to improving patient outcomes and advancing therapeutic options.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

North Carolina A&T State University is so many things to so many people, both in our state and around the country. North Carolina A&T State University is an HBCU. We are a top-flight research university, the largest historically black university (HBCU) in the country, the #1 producer of degrees awarded to African Americans in North Carolina and nationally recognized or our excellence in science, technology, mathematics and engineering (STEM) education. We are a diverse community, bound by intense pride and tradition, with fiercely loyal alumni who hold positions of importance and influence in companies and government agencies across the state, the country and the world. We are achievers, driven by a curious, limitless, fearless spirit that fuels discovery and innovation, resulting in 41 patents issued based on our research, as well as numerous spin-off and start-up companies. We are inclusive and welcoming, with students from many backgrounds and cultures, every part of our state, our nation and countries around the globe. We are passionate, driven by a desire to do more, be more and make more of a difference. Since we opened our doors in 1892, we have focused on giving every student the hands-on opportunities, core knowledge and global perspective that will lead them to make real and lasting change in their lives and the lives of others. At N.C. A&T, we have so much to be proud of, and you can learn more about those "Points of Pride" here. You can also use the links below to learn more about what makes N.C. A&T unique, from our leadership and history to our many rankings and recognitions.

National Disease Research Interchange is the source of human tissues, cells and organs for scientific research. Top 250k Enrichment Emp Range Freshness 2024 - Not Found

Nexilico, Inc. is an early-stage biotechnology firm established in 2017 and headquartered in Albany, California. The company specializes in advancing microbiome and precision medicine through the development of innovative predictive computational platforms. These platforms enhance drug design and development, focusing on improving clinical outcomes in therapeutics. By pioneering next-generation in silico microbiome technologies, Nexilico aims to deepen the scientific understanding of microbiomes and their impact on health and disease. This knowledge enables Nexilico to create novel microbiome-based approaches that support clients in optimizing drug development processes and outcomes.

Curi Bio is a biotechnology company dedicated to enhancing drug discovery and development through innovative technologies that leverage human stem cells, systems biology, and data analytics. The company aims to streamline the identification and development of new medicines by providing advanced biosystem platforms that integrate human cells and data. Curi Bio's technology offers a range of products designed for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research. By enabling in vivo maturation and alignment of various cell types, the company allows drug developers to conduct more accurate safety and efficacy tests on new drug candidates, ultimately fostering the advancement of next-generation human medicines.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Applied BioMath, LLC, established in 2013 and headquartered in Concord, Massachusetts, specializes in systems biology and pharmacology services aimed at accelerating drug research and development for biotechnology and pharmaceutical companies. The company employs advanced mathematical modeling and simulation techniques to provide predictive guidance and insights throughout the drug discovery process. Its offerings include pathway model development, target and biomarker discovery, and feasibility assessments for various drug targets. Additionally, Applied BioMath conducts analyses of competitor compounds and projects drug properties and dosing for clinical phases. The firm utilizes proprietary algorithms and high-performance computational biology to optimize decision-making and mitigate risks associated with late-stage attrition in drug development. With additional offices in Cambridge and Oakland, Applied BioMath collaborates strategically with industry leaders such as Sanofi and Xilio Therapeutics to enhance its service offerings.

Access to Advanced Health Institute is a nonprofit biotech research institute that brings together specialists, technologies, and platforms to offer accessible goods and solutions for leveraging the immune system to alleviate disease.

iMetabolic Biopharma Corporation is an early-stage precision medicine company dedicated to developing innovative therapeutics for obesity-related diseases. Utilizing its proprietary iPlatform technology, the company aims to accelerate drug discovery and deliver affordable treatments to patients with high unmet medical needs.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Co-Diagnostics, Inc. is a molecular diagnostics company based in Salt Lake City, Utah, founded in 2013. The company specializes in the development, manufacture, and marketing of advanced diagnostic technologies that focus on the detection and analysis of nucleic acid molecules, such as DNA and RNA. In addition to creating reagents for diagnostic tests, Co-Diagnostics offers self-contained lab systems that incorporate diagnostic equipment from other manufacturers. The company also leverages its proprietary technology to design targeted tests for identifying genetic markers, which can be utilized in various industries beyond infectious diseases, while licensing these tests to specific customers.

National Disease Research Interchange is the source of human tissues, cells and organs for scientific research. Top 250k Enrichment Emp Range Freshness 2024 - Not Found

Pulvinar Neuro is a neurotechnology company focused on advancing neuroscience research by offering innovative and affordable products. The company aims to support both basic and translational neuroscience research, providing researchers with cutting-edge tools to facilitate their studies. By harnessing the latest technologies, Pulvinar Neuro enables scientists to explore new solutions and deepen the understanding of brain functions.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

AivoCode Inc., established as a biotechnology company, specializes in innovative solutions for critical neurological disorders like traumatic brain injury and neurodegenerative diseases such as Alzheimer's. The company's proprietary technology revolves around unique peptides that selectively target molecular changes in affected brain regions, facilitating the delivery of various therapeutics and diagnostics. These peptides also exhibit intrinsic therapeutic properties. Notably, AivoCode's development has been solely funded through non-dilutive federal grants.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

The Indiana CTSI is dedicated to leveraging and strengthening the state’s life sciences community to achieve better health for people in Indiana.Leadership and staff at the Indiana CTSI are working to develop the best processes and resources to enable the efficient translation of scientific discoveries to patient care.Indiana CTSI programs and partnerships are designed to educate, attract and retain top research talent in the state for generations to come.

Chemeleon is a company that has developed an innovative platform technology for rapid and affordable diagnostics capable of detecting a wide array of analytes, including drugs, proteins, and viruses. Their proprietary in vitro diagnostic format delivers a colorimetric readout within minutes, visible to the naked eye, and does not require reagents, instruments, or specialized training. This decentralized testing approach empowers clinicians to extend point-of-care diagnostics and allows individuals to self-administer tests at the point of need. Chemeleon's diagnostics utilize highly selective molecular receptors combined with colorimetric nanomaterial reporters, facilitating immediate and actionable diagnoses that can significantly improve patient outcomes while reducing healthcare costs. Notably, the company developed a diagnostic for detecting beta-2-transferrin, a biomarker for Cerebrospinal Fluid leaks, resulting in substantial reductions in morbidity and healthcare expenses. With a focus on providing specificity and selectivity comparable to lab-based tests but in a fraction of the time and cost, Chemeleon's technology stands to transform healthcare accessibility, especially in resource-limited environments.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages groundbreaking research from the Akassoglou lab at Gladstone/UCSF, which identifies fibrin as a crucial factor in driving chronic innate immune activation associated with various diseases. By creating therapeutics that address neuroinflammation and vascular dysfunction, Therini Bio aims to provide potential treatments for conditions such as multiple sclerosis, thereby enhancing the quality of life for patients facing these challenging health issues.

Millennial Scientific is an advanced material and manufacturing company focused on Chromatography and allied products. Our chromatography product portfolio comprises the award-winning NanoPak-C all-carbon suite of products. They deliver high-performance extraction, separation, and purification of chemicals and biochemicals serving underserved or unserved Life- and Bio-Science market segments. These products are available as bulk stationary phase media or packed in solid-phase extraction (SPE) and liquid chromatography columns. NanoPak-C is attracting customers with analysis requirements outside the current silica-based column capabilities and seeking faster, more efficient analysis while reducing laboratory costs and solvent usage. It is benefiting customers seeking next-generation performance capabilities to separate structurally similar compounds, biologics, biobetters, or biosimilars.

Cellular Logistics, Inc. is a biotechnology company founded in 2016 and headquartered in Sun Prairie, Wisconsin. The company specializes in the development of an acellular biomaterial aimed at enhancing cell survival rates and retention in regenerative medicine therapies. This innovative biomaterial serves as a stand-alone therapeutic for applications related to cardiac and tissue vascularization and offers an effective cell delivery mechanism for regenerative treatments. By improving post-injection cell retention, Cellular Logistics aims to enhance patient outcomes in regenerative medicine.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Texas Biomedical Research Institute, established in 1941 in San Antonio, Texas, is a prominent non-profit organization dedicated to advancing scientific research on chronic and infectious diseases. Founded by Thomas B. Slick Jr., the institute is recognized internationally for its innovative approaches and high-quality basic research. It focuses on unraveling the complexities of diseases to enhance public health and safeguard communities from various health threats. Through the application of cutting-edge technologies and creative problem-solving, Texas Biomedical Research Institute aims to contribute to the global understanding of disease mechanisms and treatment options.

Neurovations, a patient care and innovation company, was founded in 1992 by CEO Dr. Eric Grigsby. Today, Neurovations is a national leader in medical device and pharmaceutical innovation, clinical research, and a world-class education program focusing in pain and neuroscience. Dr. Grigsby is deeply connected to the healthcare community through our non-profit HealthRoots Foundation. Our unwavering mission is to inspire hope and to contribute to the health and well-being of our patients and communities through integrated clinical practice, research, and education.

The Georgia Clinical & Translational Science Alliance (Georgia CTSA) is an inter-institutional magnet that concentrates basic, translational, and clinical research investigators, community clinicians, professional societies, and industry collaborators in dynamic clinical and translational research projects. Emory engaged three of its close academic partners - Morehouse School of Medicine (MSM), Georgia Institute of Technology (Georgia Tech), and the University of Georgia (UGA) - to form the Georgia CTSA. This partnership, a strategic multi-institutional alliance, offers compelling, unique, and synergistic advantages to research and patients statewide. Emory is a national leader in healthcare and biomedical research as well as an outstanding leader in clinical and translational research training and education. Morehouse School of Medicine is a nationally recognized historically black institution that brings ethnic diversity to biomedical research, addresses health disparities through successful community engagement research, and serves as a pipeline for training minority researchers. Georgia Tech is a national leader in biomedical engineering and the application of innovative systems engineering to healthcare solutions. UGA has a proven track record in outstanding basic and translational research and, as the State’s land-grant institution, offers a robust statewide network that enhances community outreach, service, and research. These institutions extend their current partnerships in healthcare, education, and cutting-edge interdisciplinary research to synergize Georgia CTSA. Created in 2017 as one of a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences, part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA), shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts and train the next generation of clinical investigators.

Stemloop is a biosensor company dedicated to harnessing biological technology to meet global challenges in chemical sensing and detection. The company focuses on developing innovative, cell-free biosensing products that simplify and enhance the testing process for chemical and molecular analysis. By utilizing genetically encoded sensing mechanisms, Stemloop aims to provide accurate and scalable solutions that are both cost-effective and accessible. This approach allows medical professionals to obtain faster and more reliable test results, ultimately improving healthcare outcomes while addressing unmet needs in laboratory testing. Through its novel technology, Stemloop seeks to revolutionize the landscape of biosensing and contribute meaningfully to various sectors.

Wake Forest School of Medicine is an educational institution based in Winston Salem, North Carolina, founded in 1902. It specializes in biomedical research and offers primary care education and training, with students gaining hands-on experience with patients from their first week of medical school. The school also provides tertiary care, which is crucial for a research and teaching hospital. Wake Forest School of Medicine has a nationally recognized research program, attracting over $400 million in extramural funding annually. It educates nearly 1,900 students and fellows, including physicians, basic scientists, and allied clinical professionals.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on leveraging artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer and infectious diseases. Utilizing its proprietary AI-immunology technology, the company is advancing a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies, two of which are currently in Phase I/IIa clinical development. In addition to its cancer therapies, Evaxion is also working on a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program in preclinical development targeting Methicillin-resistant Staphylococcus aureus and related skin and soft tissue infections. The company's innovative approach aims to enhance treatment efficacy for patients with unmet medical needs.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. The company focuses on developing therapeutics for Alzheimer's disease and related neurodegenerative disorders, particularly targeting tau proteins. Oligomerix specializes in small molecule drug discovery, with programs centered on tau oligomers and tau protease inhibitors. Additionally, the company creates antibody fragments that serve as biomarkers for drug development, diagnostic, and therapeutic applications. By leveraging its innovative research, Oligomerix aims to identify and validate new drug targets, facilitating the development of disease-modifying treatments for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Eliaz Therapeutics is focused on developing innovative medical devices aimed at treating life-threatening diseases that are currently difficult to manage. The company's flagship device utilizes a patented apheresis column designed to selectively remove galectin-3 from human blood. This device targets both bound and free galectin-3, a protein linked to various serious health conditions, including diabetes, chronic kidney disease, organ fibrosis, and cancer. By efficiently eliminating galectin-3 from the bloodstream, the device offers a less invasive treatment option with fewer side effects compared to traditional therapies. Its design leverages a proprietary capturing molecule and is compatible with existing hospital systems, facilitating its adoption in clinical settings.

Ramona is a biotechnology company that manufactures advanced microscopy toolsets designed for cellular-level research. Their core product is a microscope equipped with custom control electronics and an array of micro-cameras, enabling it to capture vast amounts of image data across large areas synchronously. This technology offers researchers a broader field of view and the ability to observe cellular dynamics in motion, facilitating more informed decision-making and accelerating scientific discoveries.

Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.

Reliant Glycosciences is a biotechnology company dedicated to developing diagnostic and prognostic tools specifically for patients with IgA nephropathy. The company focuses on creating assays that identify biomarkers associated with this condition, which possess diagnostic and prognostic value. By characterizing disease-specific biomarkers, Reliant Glycosciences aims to facilitate the development and testing of innovative, targeted therapies for IgA nephropathy. This approach not only supports the advancement of transformative treatments but also enhances the overall understanding of the disease, ultimately benefiting patients affected by this condition.

AVM Biotechnology LLC is a clinical-stage regenerative medicine company based in Seattle, Washington, focused on the discovery, development, and commercialization of innovative stem cell technologies. Founded in 2008 and led by Dr. Theresa Deisher, the company specializes in creating novel compounds aimed at enhancing organ regeneration and immune system recovery. Its offerings include a range of platforms such as Boutique Biologics, which provides personalized medicine through patient-specific biologics, and Better Biologics, designed for large-scale manufacturing of human biologics to address resistance issues associated with non-human cells. The company's lead drug, an advanced formulation of dexamethasone, aims to mobilize the body's immune cells to target cancer, autoimmune disorders, and infectious diseases. AVM Biotechnology's commitment to addressing complex medical challenges is bolstered by a Scientific Advisory Board comprised of experts in cancer and immunology.

Datirium is a developer of a scientific data analysis platform designed to enhance the accessibility of next-generation sequencing (NGS) data analysis and experiment management for biologists. The platform, known as SciDAP, facilitates collaboration between biologists and bioinformaticians by combining user-friendly, push-button analysis with advanced customization options. It visually presents analytical data, allowing biologists to quickly grasp complex concepts and identify patterns. Additionally, the platform offers interactive charts and graphs that enable scientists to delve deeper into their data for more detailed insights. By empowering biologists to perform analyses independently and automate routine tasks, Datirium aims to streamline the research process and enhance scientific productivity.

NovoMedix is a biotechnology company focused on developing novel orally available small molecules to address fibrotic disorders and certain cancer types. The company utilizes a proprietary technology platform that includes a library of small-molecule inhibitors, which have demonstrated significant efficacy in animal models for both fibrosis and cancer. Notably, some of these compounds co-target pathways that offer cardioprotective benefits and enhance the effectiveness of standard chemotherapies for triple negative breast cancer. This dual action aims to improve patient responses to treatment while significantly reducing the cardiotoxic effects commonly associated with chemotherapies, such as doxorubicin. As cardiovascular disease is a leading cause of death among breast cancer survivors, NovoMedix's approach prioritizes long-term patient health by addressing both cancer and associated heart risks. The company is working towards initiating IND enabling studies for its lead candidate, with the objective of delivering a safe and effective therapy to patients as soon as possible.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Simulations Plus is a developer of specialized software focused on Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) as well as Physiologically-Based Pharmacokinetic (PBPK) modeling and simulation. Founded in 1996 and headquartered in Lancaster, California, the company serves various sectors, including pharmaceuticals, biotechnology, chemicals, cosmetics, and food ingredients. Its software enables pharmaceutical scientists to predict key endpoints and dynamics in silico, effectively lowering research and development costs while facilitating informed decision-making. Simulations Plus employs over 60 individuals and has a consulting team based in Buffalo, New York. The company’s technology is licensed by 19 of the top 20 pharmaceutical companies, along with a range of mid-sized and smaller firms, as well as major regulatory agencies. Additionally, trusted distributors manage sales and scientific support in Asian markets.

Arc Bio is a bioscience company specializing in microbial detection through the development of innovative metagenomic next-generation sequencing solutions. The company's platform offers an integrated workflow that streamlines the process from primary sample collection to quantitative results, ensuring fast, precise, and cost-effective analyses. Arc Bio’s tools include advanced software for detecting antimicrobial resistance (AMR) genes, which automates the identification of both pathogens and antibiotic resistance sequences. This capability allows clients to quickly and accurately annotate gram-negative bacterial DNA sequences in under five minutes, enhancing the efficiency and effectiveness of microbial diagnostics.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on the research and development of innovative treatments for various central nervous system (CNS) disorders. Founded in 2013, the company specializes in creating therapeutic approaches that target neurological damage and diseases such as Alzheimer's, multiple sclerosis, spinal cord injuries, and glaucoma. Novoron’s proprietary science concentrates on lipoprotein-receptor drugs that aim to repair brain and spinal cord degeneration at both whole-receptor and micro-domain levels. The company's pipeline includes pre-clinical therapies designed to address acute conditions and demyelinating diseases, offering potential hope for patients with conditions that currently lack effective treatments.

Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.

HQ Science is a biotechnology company at the forefront of molecular diagnostics innovation.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at curing hematologic cancers, solid tumors, and rare genetic diseases. The company’s pipeline includes gene therapy programs for rare genetic disorders and chimeric antigen receptor (CAR) T cell therapies targeting various malignancies. Notable developments include MB-107, a potential curative gene therapy for X-linked severe combined immunodeficiency, and several CAR T therapies such as MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and programs targeting glioblastoma and solid tumors like breast and pancreatic cancers. Mustang Bio has established collaborations with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center to advance its research initiatives. Founded in 2015 and headquartered in New York, the company operates as a subsidiary of Fortress Biotech, Inc.

The Los Angeles Biomedical Research Institute (LA BioMed) is a 501(c)3 independent non-profit biomedical research organization that was founded in 1952. The Institute has over more than 120 principal investigators and 400 researchers in total — MD’s, MD/PhD’s, and PhD’s — working on over 1,000 research studies. They are academically affiliated with the David Geffen School of Medicine at UCLA and work in partnership with the Harbor-UCLA Medical Center. Their research is funded by many sources including: grants from the NIH and other government entities, Industry and teaching contracts and royalties, as well as private donors and other non-profit foundations.

Chosen Diagnostics is a developer of innovative biomarker diagnostic kits designed to enhance healthcare delivery for neonates. The company's primary focus is on diagnosing a prevalent and life-threatening bowel disease in preterm infants. Its diagnostic kit provides more accurate results compared to existing options, facilitating earlier medical intervention. By enabling healthcare professionals to detect critical conditions sooner, Chosen Diagnostics aims to improve treatment outcomes for thousands of low birth weight preterm infants, ultimately contributing to better health and survival rates in this vulnerable population.

Amplo Biotechnology is a biopharmaceutical company focused on developing innovative Adeno-Associated Viral (AAV) therapies aimed at treating defects related to the neuromuscular junction. These defects can lead to severe health issues, including paralysis and difficulties with breathing and swallowing. The company's lead program, AAV-Dok7, was created by Professor Yuji Yamanashi's research team at the Institute of Medical Science at the University of Tokyo, and it holds promise for addressing various congenital myasthenic syndromes and other rare, severe diseases. Amplo's therapies are administered through intravascular injection, which initiates specific molecular events necessary for effective treatment, thereby enhancing the potential for curative outcomes in affected patients.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Levisonics is a manufacturer of innovative blood coagulation instruments that specialize in non-contact analysis for both blood coagulation and fluid quality control testing. The company’s technology enables users to assess bleeding and thrombosis risks through non-invasive fluid rheological measurements. In addition to its applications in medical diagnostics, Levisonics' products are also employed in real-time monitoring of the quality of food, liquid, and gel products during production or processing. By providing a non-contact method for these critical analyses, Levisonics aims to enhance safety and quality in various industries.

Partillion Bioscience is an early-stage life science company focused on advancing single-cell analysis through its innovative platform. This novel nano vial technology enables the rapid compartmentalization and analysis of millions of single cells, facilitating the examination of biological functions, particularly concerning secreted proteins. By democratizing advanced single-cell assays, Partillion Bioscience aims to empower biotech laboratories and clients to develop more effective therapies for conditions such as cancer, autoimmune diseases, and infectious diseases.

Nanoscope Therapeutics Inc. is a biotechnology company based in Bedford, Texas, focused on developing innovative gene therapies aimed at restoring vision for individuals affected by retinal degenerative diseases, such as retinitis pigmentosa and dry age-related macular degeneration. Established in 2017, the company specializes in light-sensitive molecules and employs light-assisted gene delivery techniques to enable targeted treatment that re-sensitizes the retina, allowing patients to perceive low light levels. By utilizing a unique optogenetic approach, Nanoscope Therapeutics aims to deliver a solution for vision loss in patients where no effective cure currently exists, thereby advancing the potential for vision restoration in millions of affected individuals.

Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on the research and development of innovative treatments for various central nervous system (CNS) disorders. Founded in 2013, the company specializes in creating therapeutic approaches that target neurological damage and diseases such as Alzheimer's, multiple sclerosis, spinal cord injuries, and glaucoma. Novoron’s proprietary science concentrates on lipoprotein-receptor drugs that aim to repair brain and spinal cord degeneration at both whole-receptor and micro-domain levels. The company's pipeline includes pre-clinical therapies designed to address acute conditions and demyelinating diseases, offering potential hope for patients with conditions that currently lack effective treatments.

Xylyx Bio is a pioneering company in the field of biomaterials, dedicated to creating science-based solutions that enhance human health and life. It specializes in developing regenerative biotechnologies, offering tissue-specific extracellular matrix (ECM) substrates, clinically relevant data packages, and compound testing services. These products are designed to support pharmaceutical development, cell biology research, and regenerative medicine, providing scientists with essential components that mimic the natural cell microenvironment. By improving predictive decision-making in drug discovery, Xylyx enables researchers to develop treatments for various medical conditions, particularly focusing on fibrosis, scarring, and cellular repair in skin health and healing.

Hesperos, Inc. specializes in the development of Human-on-a-Chip microfluidic systems aimed at transforming toxicology testing and drug discovery efficacy evaluations. Founded by Michael L. Shuler and James J. Hickman, the company has pioneered advancements in creating individual organ-on-a-chip constructs and interconnected multi-organ systems. Hesperos's innovative pumpless platforms utilize serum-free cellular mediums to facilitate communication between multiple organ systems. The systems also incorporate integrated computational pharmacokinetics and pharmacodynamics modeling to assess live physiological responses through functional readouts from various tissues, including neurons, cardiac, muscle, and barrier tissues, as well as responses from the liver and pancreas. This technology enables clients to predict in vivo functions without relying on animal models, marking a significant step forward in biomedical research and development.

ID Genomics is a company that focuses on nucleotide sequence-based molecular diagnostics and the epidemiological analysis of microbial pathogens. It offers rapid and high-resolution clonal identification services tailored for clinical microbiology, research laboratories, and academia. Utilizing advanced techniques such as expanded multi-locus sequence typing (MLST) and genome-wide polymorphism annotation, the company creates customized phylogenetic and genomic analyses alongside comprehensive databases. ID Genomics also develops a genomics bar-coding-based diagnostic system that integrates molecular diagnostics with epidemiological surveillance and big-data tools. This system aids healthcare providers in accurately matching infectious agents with appropriate antibiotic treatments, enabling personalized medical care for patients with infectious diseases, often before they leave the clinic.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally invented at Cornell University, Inso Biosciences enhances the efficiency of processing cellular material. The company's platform is designed to facilitate genomic analysis, including applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. By enabling healthcare and biotechnology companies to effectively separate and isolate cellular components, Inso Biosciences aims to transform the landscape of biological sample preparation.